Overview
Biotechnology and pharmaceutical manufacturers must recognize, understand, and address many legal and regulatory requirements associated with the research, development, pricing, promotion, marketing, and selling of their respective services and products—domestically and internationally.
Significant scrutiny on these industries from the public; federal, state, and international regulators; elected officials; and enforcement agencies continues. Therefore, entities operating in these industries must remain even more vigilant and knowledgeable about the legal and regulatory parameters affecting their companies in order to stay compliant and proactive in order to minimize risk.
Epstein Becker Green counsels companies and institutions operating in the different segments of biotechnology and pharmaceutical industries domestically and internationally. We provide comprehensive legal services relating to all aspects of the development of products, the U.S. Food and Drug Administration (FDA) regulatory approval process, government and third-party reimbursement concerns, and post-approval marketing, commercialization, and compliance requirements. Firm attorneys publish and present extensively at leading industry events and work actively on behalf of firm clients to both educate and advocate to federal and state government agencies and regulators on significant industry issues.
Services/Scope of Practice
Development of Life Science Products and FDA Regulatory Approval
- Providing FDA counseling relating to clinical trial registries and databases, grant-making procedures, and relationships with physicians investigators, and research institutions
- Developing and negotiating co-development, co-promotion, outsourcing, and other strategic research, development, and collaboration agreements
- Providing FDA counseling relating to labeling and advertising claims
Government and Third-Party Reimbursement
- Counseling on government pricing programs, including Medicaid Best Price, Average Sales Price, Competitive Acquisition Program, the Federal Supply Schedule, and the Public Health Service Act, and on VA pricing issues
- Providing counseling and strategic planning assistance regarding federal and state drug and device reimbursement programs
- Advising on the processes and strategies for obtaining coverage, coding, and payment for drugs and devices by government and private payors
- Providing regulatory counseling regarding product discount/rebate arrangements with distributors, GPOs, managed care organizations, long-term care facilities, physicians, institutions, specialty pharmaceutical suppliers, federal and state purchasers (including SPAPs and other state and federal pharmaceutical programs), and other purchasers
- Providing antitrust counsel related to manufacturer pricing issues
- Counseling on license agreements and co-promotional activities
Post-Approval Marketing, Commercialization, and Compliance
- Providing all facets of fraud and abuse counseling to manufacturers and their direct and indirect customers and/or purchasers relating to sales programs, marketing initiatives, and other collaborative programs and relationships, including disease management, medication therapy management, coupons, samples and sample cards, reimbursement support, grants, and patient assistant programs
- Providing advice relating to all aspects of health reform regulations, including the Sunshine Act and state reporting laws
- Supporting and counseling on manufacturer new product launches
- Providing health regulatory counsel relating to distribution and fee-for-service arrangements with MCPs and consumers
- Providing FDA counseling relating to promotional matters, non-promotional activities, continuing medical education activities, and good clinical and laboratory practices
- Providing all facets of counsel regarding post-market clinical trial research programs and grant administration
- Counseling on licensure and other accreditation standards
- Providing HIPAA privacy and security counseling relating to manufacturing, research, and marketing issues
Investigations, Litigation, and Administrative Matters
- Defending manufacturers in connection with false claim qui tam actions and other federal, state, and congressional health care fraud investigations and inquiries
- Negotiating corporate integrity agreements (CIAs) with the OIG
- Assisting with the implementation and monitoring of CIA compliance
- Providing counsel regarding the submission of voluntary disclosures to the OIG and/or other relevant regulators
- Defending manufacturers and their research partners in private actions related to clinical trial noncompliance and misconduct
- Preparing and assisting manufacturers for appearances at FDA administrative hearings
- Assisting manufacturers in responding to warning letters, notice-of-violation letters, and congressional inquiries
Corporate Compliance
- Developing and implementing all aspects of corporate compliance programs for manufacturers and their direct and indirect customers
- Conducting corporate effectiveness reviews/assessments of corporate compliance programs
- Developing training programs on corporate compliance for marketing and sales forces
- Assisting with the development of reporting systems and compliance monitoring and auditing priorities
- Assisting manufacturers with gap assessments and Board assessments
- Providing counsel in connection with internal compliance investigations
- Developing clinical trial research corporate compliance programs for manufacturers, clinical research organizations, and site management organizations, including compliance with Good Clinical Practices, human subject protection compliance procedures, and procedures regarding investigator-initiated research
- Developing research compliance programs addressing relationships with research sites, researchers, vendors, professional organizations, independent foundations, and other participants in the clinical research process
Policy and Legislation
- Monitoring and analyzing pending federal and state legislation, rulemaking, regulations, and guidance
- Providing assistance with the submission of comments in connection with pending legislation and proposed rules, regulations, and guidance
- Assisting with the preparation of testimony in connection with pending legislation
- Providing counsel regarding federal and state marketing, disclosure, sales, gift, compliance program, pricing, clinical trials, pedigree, and related reporting requirements
- Providing legislative industry updates and analyses
Federal and State Transparency Reporting
- Counseling clients on federal and state reporting requirements
- Conducting gap assessments
- Correcting compliance implementation deficiencies
- Addressing infrastructure and resource matters
- Implementing aggregate spend reporting systems
- Drafting policies, procedures, and working instructions
- Training employees, vendors, and health care professionals
- Responding to government agencies and proposed regulations
- Analyzing preemption matters
- Informing clients of federal and state law developments
Read less
Focus Areas
Services
Industries
Trending Issues
Experience
Contacts
- Member of the Firm
- Board of Directors / Member of the Firm
- Member of the Firm
Media
Events
Upcoming Events
Past Events
- May 8-10, 2024
Insights
Insights
- BlogsPodcast: Unveiling Gender-Affirming Care: Why It Matters and What’s at Stake – Diagnosing Health Care2 minute read
- Blogs
Litigating Nutrition: Class Action Battles Over Dietary Supplements – Speaking of Litigation Video Podcast
41 minute read - Media CoverageJames Boiani Quoted in “Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval”5 minute read
- PublicationsThe IRA: Reducing Inflation or Threatening Patient Access?2 minute read
- Media CoverageGeorge Breen Quoted in “Supreme Court Ruling Changes View of Wrongful Intent”5 minute read
- PublicationsThe Path to Prevention: Charting the Course for a Healthier Nation2 minute read
- PublicationsFive Commissioners and a Vote on Noncompetes to Come2 minute read
- PublicationsThe Vaccine Pricing Assault That Threatens Public Health3 minute read
- Media CoverageTheodora McCormick Quoted in “‘Vague’ NY Law Looms for the Vitamin Shoppe, Other Supplement Retailers”3 minute read
- Media CoverageTeddy McCormick Quoted in “NPA to Seek Injunction Against NY Law Related to Weight Loss Supplements”4 minute read
- PublicationsFTC Continues Investigation into PBM Practices2 minute read
- BlogsFDA Releases Draft Guidance on New Dietary Ingredient Notification Procedures, Timelines11 minute read
- PublicationsFDA and OHRP Issue Joint Draft Guidance on Content, Organization, and Presentation of Consent Forms for Research ...9 minute read
- Firm AnnouncementsEpstein Becker Green Continues to Materially Expand Employee Benefits and Executive Compensation Capabilities with ...3 minute read
- Publications
Will Religious Freedom Claims Trump Public Health? Braidwood and HIV Prevention
2 minute read - Media CoverageRichard Hughes Quoted in “ObamaCare Faces Key Hearing After Texas Ruling”2 minute read
- Media CoverageRichard Hughes Quoted in “4 Argument Sessions Benefits Attys Should Watch in March”4 minute read
- BlogsVideo: Braidwood v. Becerra – Challenging the Affordable Care Act’s Preventive Services Coverage Provision – ...2 minute read
- Media CoverageRichard Hughes Quoted in “Affordable Care Act Preventive Services Under Threat: Previewing Braidwood Oral Arguments” ...4 minute read
- Media CoverageRichard Hughes Quoted in “Doc Pay Patch Could Emerge in Scaled-Back Health Package; Budget Talks Continue”2 minute read
- Media CoverageMarjorie Scher Quoted in “Citing U.S. Supreme Court Decision, Health System Sues Medicare Advantage Plan for Past 340B ...4 minute read
- Media CoverageLesley Yeung Quoted in “How Trump Could Weaken Medicare Drug Pricing Negotiations”4 minute read
- PublicationsEnsure Equity and Feasibility in Updating Meningococcal Vaccine Recommendations2 minute read
- PublicationsSponsored Genetic Testing Programs: Compliance Considerations Following DOJ False Claims Act Settlement13 minute read
- PublicationsClinical Preventive Guidelines Should Foster Patient Access: A Reply to Killelea and Johnson6 minute read
- Media CoverageAmy Lerman Quoted in “Patient Care, Policy & More: A Look at This Year’s Virtual Care Trends”5 minute read
- Media CoverageJames Boiani Quoted in “FDA Braces for High Court, Final Rule Moves in Election Year”3 minute read
- Media CoverageRichard Hughes Quoted in “The RSV Shot for Babies Was Supposed to Save Lives. Then Nobody Could Get It.”13 minute read
- PublicationsBraidwood v Becerra’s Vaccine Access Threat3 minute read
- Publications
In Genesis Case, South Carolina District Court Scraps HRSA Interpretation of “Patient” Under 340B Statute
9 minute read - Media CoverageConnie Wilkinson Quoted in “Stelara Biosimilar Tests Market Impact of Drug Price Program”3 minute read
- BlogsSharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft ...14 minute read
- PublicationsPaving the Way for Prevention Over the Counter3 minute read
- PublicationsQuadrivalent vs Trivalent Influenza Vaccines: Not a Simple Switch2 minute read
- PublicationsCMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation ...4 minute read
- PublicationsPreventive Antibody Products Are Immunizations2 minute read
- Media CoverageRichard Hughes Quoted in “An R.S.V. Shot for Infants Is in Short Supply. Here’s What to Know”4 minute read
- PublicationsCalifornia Enacts Statute That Furthers Efforts to Move Toward a Unified Health Care Financing System11 minute read
- Media CoverageRichard Hughes Quoted in “RSV Vaccines Aren’t Covered by Medicare for These Vulnerable Groups”2 minute read
- BlogsCongress May Have a Vision for Psychedelic Regulation in the US5 minute read
- PublicationsORI Releases Notice of Proposed Rulemaking to Update 2005 Public Health Service Policies on Research Misconduct ...7 minute read
- BlogsFull Steam Ahead: FDA Releases Proposed LDT Rule in Advance of Looming Government Shutdown4 minute read
- Publications
Checking In on How SuperValu Has Altered FCA Litigation
4 minute read - PublicationsState Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of ...25 minute read
- PublicationsFTC Warns Against Contract Provisions It Believes Could Impede Its Investigations2 minute read
- PublicationsFTC’s Fight with House Judiciary Committee Goes Public2 minute read
- PublicationsAdditional Withdrawals of Long-Standing Guidance and Newly Proposed Merger Guidelines2 minute read
- PublicationsEuropean Commission Adopts an Adequacy Decision for a New EU-U.S. Data Privacy Framework6 minute read
- PublicationsPotential Hart-Scott-Rodino Changes on the Horizon3 minute read
- PublicationsWhat’s on the Agenda? Laboratory Developed Tests Added to the Unified Regulatory Agenda Signals FDA Movement Toward New ...26 minute read